Clinical Evaluation of Platelet Concentrates Either in Plasma or in Additive Solution

Abstract

Background and Objectives. Platelet concentrates (PC) obtained from Buffy-Coat (BC) may be diluted in a platelet additive solution (PAS). These PCs may reduce plasma-related adverse reactions. We have tried to assess the relationship between PAS PCs and adverse reactions. Materials and Methods. During 6 months, patients treated with intensive chemotherapy, participated in a prospective study and were randomly assigned to receive, on a prophylactic basis, PCs in either plasma or PAS-2. Five iso-group BCs were pooled diluted in either plasma or PAS-2. One hour after each transfusion, corrected count increments (CCIs) were calculated, presence of hemorrhage and adverse reactions were recorded. Results. Platelet increment, 1-hour platelet count, and corrected count increments (CCI) after transfusion in both groups were similar. There were more transfusion-dependent adverse reactions in plasma group. Conclusion. Use of PAS-2 resulted in less transfusion related reactions; therefore, we recommend synthetic additive solutions to dilute PCs.